Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore


HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024. In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package. ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy.

Title: Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys
Presenter: Li Ou, Ph.D.
Session title: AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV Delivery
Presentation type: Oral Presentation
Date and Time: Friday, May 10, 3:45pm - 4:00pm

This presentation focuses on Avirmax's lead candidate ABI-110 for wet AMD and PCV using a proprietary novel capsid AAV2.N54. AAV2.N54 was developed through capsid engineering and showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM  rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations.

Title: Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing
Presenter: Li Ou, Ph.D.
Session title: AAV Vectors - Product Development Manufacturing and Approval Considerations
Presentation type: Poster Presentation
Date and Time: Friday, May 10, 12:00 pm

This presentation focuses on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in the publication in Molecular Therapy from Avirmax, the Sf9 system has advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems.

About Avirmax Inc.
Avirmax Inc. is a San Francisco-based company specializing in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Visit us at avirmax.com for more information.

References

Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, Liu F, Yu Y, Leib RD, Li Y, Lin K, Huynh D, Li S, Ou L. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2023 Nov 20:S1525-0016(23)00623-8.

Contact

Please contact
June Song, Associate Director for Operations
Email: [email protected]
Tel: +1-510-641-0201

Address

25503 Whitesell Street
Hayward 94545 CA
USA

SOURCE Avirmax


These press releases may also interest you

at 14:01
Stratus® Medical announces continued expansion of its intellectual property coverage in Europe with additions to its global patent portfolio for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode and registration of a Community design for new platform technology in development
Stratus® Medical, a company focused on improving clinical outcomes for chronic pain patients by advancing radiofrequency (RF) technology for the treatment of pain, announced today the expansion of patent protection in Europe for its NIMBUS®...

at 13:50
Newborn Screening Emergency: Urgent Call for Action to Identify 10,000+ Undiagnosed Rare Diseases
The push for a transformative U.S.-India partnership in newborn screening (NBS) sets the stage for a seismic shift in tackling rare diseases, spotlighting the need to prepare for the digital AI revolution in global healthcare. Advocates are rallying...

at 13:39
FDA to Hold Listening Session as Part of Broader Work to Optimize Use of, and Processes for, Advisory Committees
Today, the U.S. Food and Drug Administration announced it will host a listening session in June as part of its broader work to optimize the use of, and processes for, advisory committees. This virtual public meeting will focus on the composition of...

at 13:35
Health-E Commerce® shares 5 ways to use FSA or HSA funds to support women's health
The hormonal changes that women experience throughout their lives put them at increased risk for serious or chronic health conditions like diabetes, stroke, obesity, and even breast cancer. Fortunately, managing...

at 13:31
CHOP Study Finds Healthcare Providers Play Crucial Role in Guiding Autistic Adolescents and Their Families into Adulthood
Healthcare providers are a vital resource for autistic adolescents and their families as they prepare for the transition to adulthood, which may include learning to drive, according to a new study from researchers at Children's Hospital of...

at 13:30
LaserAway - Nation's Leading Aesthetic Dermatology Company - Adds Former Orangetheory CMO and Amazon Exec Kelly Lohr as Chief Customer Officer
The nation's leading aesthetic dermatology chain, LaserAway, has hired Kelly Lohr as its first-ever Chief Customer Officer. Overseeing the end-to-end customer journey ? including customer acquisition and customer engagement, retention, and loyalty ?...

More news about Health...


News published on and distributed by: